Research and Reviews in the Fastlane 090

This study prospectively looks at 106 patients with either DVT or PE who were identified as low risk based on the Hestia criteria. All of the patients were started on rivaroxaban (a Factor Xa inhibitor) and none had VTE recurrence (while on anticoagulation), major bleeding events or death due to VTE. This study further supports outpatient management for low risk VTE but a randomized controlled trial is needed (keep your eye out for the MERCURY-PE study) Recommended by Anand Swaminathan Further reading: SGEM #126: Take me to the Rivaroxaban — Outpatient treatment of VTE (The Skeptics Guide to EM) Research and critical appraisalHorowitz BZ, et al. Droperidol–behind the black box warning. Acad Emerg Med. 2002; 9(6):615-8. PMID: 12045077 An older, but outstanding blow by blow look at the cases which led to the FDA black box warning on droperidol in the U.S. The authors examine each case submitted and find some curiosities:-55 of the 93 deaths reported were submitted on the same day The overwhelming majority of adverse event cases were reported with significantly higher doses of the drug than that routinely used in the EDThe authors also nicely summarize what we knew about alternative agents at the time of the editorial (2002), and is well worth reading for all those wondering why such a useful drug has been eliminated from the formulary at many hospitals. HT to Sean Nordt and Rob Orman for their discussion of the issue and editorial on ERCast. Recommended by Jeremy...
Source: Life in the Fast Lane - Category: Emergency Medicine Authors: Tags: Airway Clinical Research Emergency Medicine Intensive Care Neurology R&R in the FASTLANE Respiratory Review critical care EBM Education recommendations research and reviews Source Type: blogs